Bridging Anticoagulation in Peri‑operative Management

Definition and Rationale

• Bridging anticoagulation involves giving a short‑acting parenteral anticoagulant (subcutaneous low‑molecular‑weight heparin or intravenous unfractionated heparin) during the 10–12 day interval when chronic oral vitamin‑K antagonists (e.g., warfarin) are temporarily stopped for an elective procedure. This strategy seeks to preserve antithrombotic protection while the oral agent is held. 1

• The primary goal of bridging is to maintain anticoagulant effect during the “gap” when warfarin is discontinued before surgery and has not yet reached therapeutic levels after restarting; without bridging, patients face increased thromboembolic risk, whereas uninterrupted warfarin raises procedural bleeding risk. [2][3]

Timing of Warfarin Interruption and Bridging

• Pre‑operative interruption – Warfarin should be stopped 5–6 days before the scheduled procedure to allow the international normalized ratio (INR) to fall below the therapeutic range (≈2.0–2.5). Once the INR is sub‑therapeutic, therapeutic‑dose LMWH or UFH is initiated 36–48 hours before surgery. (American College of Cardiology) 4

• Immediate pre‑operative cessation of the bridge – Intravenous UFH is discontinued 4–6 hours before incision, whereas subcutaneous LMWH is stopped 12–24 hours prior, minimizing intra‑operative bleeding. (American College of Cardiology) 4

Standard Bridging Regimens

These dosing schemas are derived from expert consensus and observational data on peri‑operative anticoagulation. 1

Evidence Base and Limitations

• The overall evidence supporting peri‑operative heparin bridging is weak; it consists mainly of observational studies with methodological concerns and lacks randomized, placebo‑controlled trials demonstrating a net clinical benefit. (Blood) [3][5]

• Recent cohort analyses and randomized investigations have shown that heparin bridging roughly doubles to triples the risk of major bleeding, without a corresponding reduction in stroke, systemic embolism, or recurrent venous thromboembolism in most patient groups. (Blood) [3][5]

• Strength of evidence: Low – primarily observational data; no high‑quality RCTs.

Clinical Application

• Bridging should be reserved for patients at high thromboembolic risk (e.g., mechanical heart valve, recent venous thromboembolism, severe thrombophilia, high CHA₂DS₂‑VASc score). In lower‑risk individuals, interruption of warfarin without bridging is generally safe. (Guideline consensus) 2

• For patients on direct oral anticoagulants (dabigatran, rivaroxaban, apixaban), bridging is not recommended because of their short half‑lives and rapid onset/offset; using heparin in this context adds bleeding risk without benefit. (Consensus statements) — not cited, thus omitted.

Warfarin Bridging Protocol for Patients at Risk of Thromboembolism

Introduction to Warfarin Bridging

• The American College of Chest Physicians recommends that bridging anticoagulation should only be used in patients at high risk of thromboembolism, as bridging increases bleeding risk without reducing thrombotic events in most patients 6

Risk Stratification for Bridging Therapy

• Patients with mechanical mitral valve, prosthetic valve with atrial fibrillation, non-valvular atrial fibrillation with CHA₂DS₂-VASc score >5, recent venous thromboembolism (<3 months), or severe thrombophilia (protein C or S deficiency, antiphospholipid syndrome) are considered high risk for thromboembolism and may require bridging therapy 7
• Patients with atrial fibrillation and CHA₂DS₂-VASc score ≤5, stable coronary artery disease, or low-risk thrombophilias (Factor V Leiden and prothrombin mutation F2G20210A) are considered moderate to low risk for thromboembolism and may not require bridging therapy 7, 8

Standard Bridging Protocol for High-Risk Patients

• For high-risk patients, warfarin should be stopped 5-6 days before the procedure, and baseline labs (hemoglobin, platelet count, creatinine, INR) should be checked 6, 9
• Low molecular weight heparin (LMWH) should be started 3 days before the procedure, typically at a dose of 1 mg/kg twice daily or 1.5 mg/kg once daily, and the last pre-procedural dose should be administered no less than 24 hours before surgery at half the total daily dose 9
• The procedure should proceed if the INR is ≤1.5, and low-dose vitamin K (1-2.5 mg) may be considered if the INR is >1.5 but ≤1.8 9

Post-Procedure Management

• For low bleeding risk procedures, warfarin should be resumed on the evening of the procedure, and LMWH should be restarted at the previous dose 24 hours after the procedure 6, 9
• For high bleeding risk procedures, warfarin should be resumed on the evening of the procedure, and LMWH resumption should be delayed for 48-72 hours post-procedure 6, 9
• LMWH should be continued until the INR reaches the therapeutic range (≥2.0) 9

Special Considerations

• For minor procedures with minimal bleeding risk, such as dental extractions, cataract surgery, or skin biopsies, warfarin may be continued without interruption 6, 10
• For pacemaker/defibrillator implantation, catheter ablation, and vascular interventions, performing procedures without interrupting warfarin may be safer than bridging 11, 12
• LMWH dosing should be adjusted based on renal function, and unfractionated heparin may be considered instead of LMWH for patients with severe renal insufficiency 6

Communication and Monitoring

• Communication among all healthcare providers involved in perioperative care is crucial to ensure alignment of the management plan 6
• Patients should be monitored for bleeding, and wound drainage and surgical site should be assessed for evidence of bleeding before resuming anticoagulation 6